CRISPR-Powered Liquid Biopsies in Cancer Diagnostics.

Area of Science:

• Biotechnology
• Molecular Diagnostics
• Oncology

Background:

• Liquid biopsies offer minimally invasive cancer detection by analyzing biomarkers in blood.
• Current assays struggle with the low concentrations of circulating tumor nucleic acids.
• Existing methods lack the sensitivity and specificity required for early cancer detection.

Purpose of the Study:

• To review current Clustered Regularly Interspaced Short Palindromic Repeats diagnostics (CRISPR-Dx) platforms.
• To assess the analytical potential of CRISPR-Dx for cancer biomarker discovery.
• To highlight applications in early diagnosis, disease monitoring, and point-of-care testing.

Main Methods:

• CRISPR-Dx utilizes gene editing tools for highly specific nucleic acid detection.
• CRISPR assays are often combined with isothermal nucleic acid amplification.
• CRISPR-Dx platforms are evaluated for sensitivity and specificity.

Main Results:

• CRISPR-Dx achieves high specificity in detecting nucleic acids.
• Combined with amplification, CRISPR-Dx offers sensitivity comparable to digital PCR.
• CRISPR-Dx assays are adaptable for point-of-care (POC) applications.

Conclusions:

• CRISPR-Dx presents a promising technology for cancer biomarker detection.
• The technology facilitates early cancer diagnosis and monitoring.
• CRISPR-Dx offers a faster and easier development pathway for point-of-care diagnostics.